Hosted on MSN12h
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...
Harvard Medical School13h
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Petri Dish: One Boston biotech shuts down, another bags $90M
In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...
CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit
CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...
VisionHealth announces management transition as company prepares for U.S. launch of Kata® app
Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market opportunitiesDr. Sabine ...
Vertex grew headcount 13% for the second straight year
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...